Charles River Laboratories International, Inc. (NYSE:CRL) Shares Acquired by North Growth Management Ltd.

North Growth Management Ltd. raised its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 18.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 39,000 shares of the medical research company's stock after purchasing an additional 6,000 shares during the quarter. North Growth Management Ltd. owned 0.08% of Charles River Laboratories International worth $7,168,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Wellington Management Group LLP boosted its holdings in Charles River Laboratories International by 135,927.9% during the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company's stock worth $736,819,000 after buying an additional 3,738,018 shares during the last quarter. State Street Corp increased its holdings in shares of Charles River Laboratories International by 2.0% in the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company's stock worth $419,601,000 after acquiring an additional 41,421 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Charles River Laboratories International by 40.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company's stock valued at $346,821,000 after purchasing an additional 509,163 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Charles River Laboratories International by 6.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 515,222 shares of the medical research company's stock worth $101,483,000 after purchasing an additional 32,311 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in Charles River Laboratories International by 21.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock worth $95,086,000 after buying an additional 85,759 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Price Performance

NYSE:CRL traded down $0.98 during trading hours on Wednesday, hitting $153.92. 1,278,385 shares of the stock traded hands, compared to its average volume of 978,506. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. The stock has a 50 day moving average price of $177.99 and a 200 day moving average price of $191.98. Charles River Laboratories International, Inc. has a 1 year low of $150.79 and a 1 year high of $275.00. The company has a market cap of $7.87 billion, a price-to-earnings ratio of 19.26, a price-to-earnings-growth ratio of 6.47 and a beta of 1.37.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on CRL shares. TD Cowen lifted their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a research report on Monday, November 11th. The Goldman Sachs Group decreased their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating for the company in a research report on Thursday, January 23rd. JPMorgan Chase & Co. cut their price target on shares of Charles River Laboratories International from $215.00 to $175.00 and set a "neutral" rating on the stock in a research report on Monday, February 3rd. Evercore ISI lifted their target price on Charles River Laboratories International from $190.00 to $225.00 and gave the company an "in-line" rating in a research report on Thursday, November 7th. Finally, William Blair cut shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 22nd. Three equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of "Hold" and a consensus price target of $200.79.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).